Chronic administration of propranolol improves vascular contractile responsiveness in portal hypertensive rats

European Journal of Clinical Investigation

Volumn 27, Issue 7, 1997, Pages 550-555

  Huang, Y T ^a   Lin, H C ^a   Tsai, J F ^a   Hou, M C ^a   Hong, C Y ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Contractile response; Portal hypertension; Propranolol; Superior mesenteric artery; Vasopressin

Indexed keywords

POTASSIUM CHLORIDE; PROPRANOLOL; VASOPRESSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTICLE; CONTROLLED STUDY; HEART INDEX; INTRAGASTRIC DRUG ADMINISTRATION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; RAT; SUPERIOR MESENTERIC ARTERY; VASCULAR RESISTANCE; VEIN LIGATION;

EID: 0030878655     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1997.1590708.x     Document Type: Article

References (40)

1. Genecin P, Groszmann RJ. The biology of portal hypertension. In: Arias IM, Boyer JL, Fausto N, Jakoby WB, Schachter DA, Shafritz DA, eds. The liver: biology and pathohiology, 3rd edn. New York: Raven Press, 1994:1327-41.
2. Lebrec D. Pharmacological treatment of portal hypertension: hemodynamic effects and prevention of bleeding. Pharmacol Therap 1994;61:65-107.
3. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995;22:332-54.
4. Rodriguez-Perez F, Groszmann RJ. Pharmacologic treatment of portal hypertension. Gastroenterol Clin N Am 1992;21:15-40.
5. Bosch J, Mastai R, Kravetz D et al. Effects of propranolol on azygous blood flow and hepatic and systemic hemodynamics in cirrhosis. Hepatology 1984;4:1200-5.
6. Lin H-C, Soubrane O, Cailmail S, Lebrec D. Early chronic administration of propranolol reduces the severity of portal hypertension and portal-systemic shunts in conscious portal vein stenosed rats. J Hepatol 1991;13:213-19.
7. Sarin SK, Groszmann RJ, Mosca PG et al. Propranolol ameliorates the development of portal-systemic shunting in a chronic murine schistomiasis model of portal hypertension. J Clin Invest 1991; 87:1032-6.
8. Benoit JN, Granger DN. Splanchnic hemodynamics in chronic portal hypertension. Semin Liver Dis 1986;6:287-98.
9. Sieber CC, Groszmann RJ. Nitric oxide mediates hyporeactivity to vasopressors in mesenteric vessels of portal hypertensive rats. Gastroenterology 1992;103:235-9.
10. Karatapanis S, McCormick PA, Kakad S et al. Alteration in vascular reactivity in isolated aortic rings from portal vein-constricted rats. Hepatology 1994;20:1516-21.
11. Kiel JW, Pitts V, Benoit JN, Granger DN, Shepherd AP. Reduced vascular sensitivity to norepinephrine in portal hypertensive rats. Am J Physiol 1985;248:G192-5.
12. 1-adrenoceptors of portal hypertensive rats. Br J Pharmacol 1994;111:439-44.
13. Mesh CL, Joh T, Korthuis RJ, Granger DN, Benoit JN. Intestinal vascular sensitivity to vasopressin in portal hypertensive rats. Gastroenterology 1991;100:916-21.
14. Joh T, Granger DN, Benoit JN. Endogenous vasoconstrictor tone in intestine of normal and portal hypertensive rats. Am J Physiol 1993;264:H171-7.
15. Murray BM, Palier MS. Decreased pressor reactivity to angiotensin II in cirrhotic rats: evidence for a post-receptor in angiotensin action. Circ Res 1985;57:424-31.
16. Sitzmann JV, Li S-S, Wu Y-P, Groszmann RJ, Buckley GB. Decreased mesenteric vascular response to angiotensin II in portal hypertension. J Surg Res 1990;48:341-4.
17. Chojkier M, Groszmann RJ. Measurement of portal systemic shunting in the rat by using γ-labeled microspheres. Am J Physiol 1981;240:G371-5.
18. Huang, Y-T, Wang G-F, Yang MCM, Chang S-P, Lin H-C, Hong C-Y. Vascular hyporesponsiveness in aorta from portal hypertensive rats: possible sites of involvement. J Pharmacol Exp Ther 1996; 278:535-41.
19. Albillos A, Colombato LA, Groszmann RJ. Vasodilatation and sodium retention in prehepatic portal hypertension. Gastroenterology 1992;102:931-5.
20. Mulvany MJ, Aalkjaer C. Structure and function of small arteries. Physiol Rev 1990;70:921-61.
21. Weigert AL, Martin P-Y, Niederberger M et al. Endothelium-dependent vascular hyporesponsiveness without detection of nitric oxide synthase induction in aorta of cirrhotic rats. Hepatology 1995;22:1856-62.
22. Reichen J. Liver function and pharmacological considerations in pathogenesis and treatment of portal hypertension. Hepatology 1990;11:1066-78.
23. Folkow B. The structural factor in hypertension with special emphasis on the altered geometric design of the systemic resistance arteries. In: Laragh JH, Brenner BM, eds. Hypertension: pathophysiology, diagnosis and management, 2nd edn. New York: Raven Press, 1995:481-502.
24. Sieher CC, Lee F-Y, Groszmann RJ. Long-term octreotide treatment prevents vascular hyporeactivity in portal-hypertensive rats. Hepatology 1996;23:1218-23.
25. Groszmann RJ. Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences. Hepatology 1994;20:1359-63.
26. Huang Y-T, Lo J-W, Lin H-C, Tsai Y-T, Hong C-Y, Yang MCM. Change in vascular cAMP and cGMP contents in portal hypertensive rats. Pharmacology 1995;50:86-91.
27. Cahill PA, Foster C, Redmond EM, Gingalewski C, Wu Y, Sitzmann JV. Enhanced nitric oxide synthase activity in portal hypertensive rabbits. Hepatology 1995;22:598-606.
28. Niederberger M, Gines P, Tsai P et al. Increase aortic cyclic guanosine monophosphate concentration in experimental cirrhosis in rats: evidence for a role of nitric oxide in the pathogenesis of arterial vasodilation in cirrhosis. Hepatology 1995;21:1625-31.
29. Kuriyama H, Kitamura K, Nabata H. Pharmacological and physiological significance of ion channels and factors that modulate them in vascular tissues. Pharmacol Rev 1995;47:387-573.
30. Lin H-C, Soubrane O, Lebrec D. Prevention of portal hypertension and portosystemic shunts by early chronic administration of clonidine in conscious portal vein-stenosed rats. Hepatology 1991;14: 325-30.
31. ω-nitro-L-arginine ameliorates portal-systemic shunting in portal-hypertensive rats. Gastroenterology 1993;105:1464-70.
32. Lin H-C, Yang MC-M, Hou M-C et al. Effects of long-term administration of octreotide in portal vein stenosed rats. Hepatology 1996;23:537-43.
33. Prichard BNC, Cruickshank JM. Beta blockade in hypertension: past, present, and future. In: Laragh JH, Brenner BM, eds. Hypertension: pathophysiology, diagnosis, and management, 2nd edn. New York: Raven Press, 1995:2827-59.
34. Wu Z-Y, Benoit JN. Nonreceptor-mediated intestinal vasoconstriction in portal hypertensive rats. Am J Physiol 1994;267:H370-5.
35. Sogni P, Sabry S, Moreau R, Gadano A, Lebrec D, Dinh-Xuan AT. Hyporeactivity of mesenteric resistance arteries in portal hypertensive rats. J Hepatol 1996;24:487-90.
36. Huang Y-T, Yu P-C, Lee M-F, Lin H-C, Hong C-Y, Yang MCM. Decreased vascular contractile and inositol phosphate responses in portal hypertensive rats. Can J Physiol Pharmacol 1995;73:378-82.
37. Sieber CC, Groszmann RJ. In vitro hyporeactivity to methoxamine in portal hypertensive rats: reversal by nitric oxide blockade. Am J Physiol 1992;262:G996-1001.
38. Michielson PP, Boeckxstaens GE, Sys SU, Herman AG, Pelckmans PA. Role of nitric oxide in hyporeactivity to noradrenaline of isolated aortic rings in portal hypertensive rats. Eur J Pharmacol 1995;273:167-74.
39. Heinemann A, Stauber RE. The role of inducible nitric oxide synthase in vascular hyporeactivity of endotoxin-treated and portal hypertensive rats. Eur J Pharmacol 1995;278:87-90.
40. Bomzon A, Blendis LM. The nitric oxide hypothesis and the hyperdynamic circulation in cirrhosis. Hepatology 1994;20:1343-50.